Story thread · 2 reports / 2 sources
Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder
seekingalpha.com · 15d
First report: AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial — investing.com, 15d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.